

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/770,943	01/25/2001	Eyal Raz	UCAL173CON	8209
24353	7590 11/15/2006		EXAMINER	
BOZICEVIC, FIELD & FRANCIS LLP			DUFFY, PATRICIA ANN	
1900 UNIVERSITY AVENUE SUITE 200			ART UNIT	PAPER NUMBER
EAST PALO	ALTO, CA 94303	1645		
			DATE MAILED: 11/15/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

2) Notice of Draftsperson's Patent Drawing Review (PTO-948)

Information Disclosure Statement(s) (PTO/SB/08)

Paper No(s)/Mail Date. _

Other:

5) Notice of Informal Patent Application

Application/Control Number: 09/770,943

Art Unit: 1645

DETAILED ACTION

Upon consideration of Applicant' newly added claim and claim amendments, the following species requirement is set forth. The examiner apologizes for any inconvenience to Applicants in this matter.

Election/Restrictions

This application contains claims directed to the following patentably distinct species of peptide conjugate: autoantigen and autoantibody. The species are independent or distinct because an autoantigen has different structural and functional characteristics as compared to an autoantibody. An autoantigen does not necessarily produce autoantibodies and could alternatively produce cytotoxic T cells. The autoantibody does not have to bind the recited autoantigen and therefore, the search for the two are not overlapping in nature. Further, the consideration for examination issues with respect to pharmaceutical compositions comprising autoantigens and autoantibodies are clearly distinct each from the other since the two are not liked to the same disease or disorder.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 36 and 40-43 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the

Application/Control Number: 09/770,943

Art Unit: 1645

election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Patricia A. Duffy whose telephone number is 571-272-0855. The examiner can normally be reached on M-Th 7:30 pm - 7:00 pm.

Application/Control Number: 09/770,943

Art Unit: 1645

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeff Siew can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Para Deg Patricia A. Duffy Primary Examiner Art Unit 1645